AKT1 and non-small cell lung carcinoma: Similar to rapamycin, everolimus induces AKT activation while inhibiting mTOR signaling in human cancer cells, including NSCLC cells, as well as in tumor biopsies (Wang et al., 2008; O'Reilly et al., 2006).